Home / People / Sarah Hanson
Picture of Hanson Sarah

Sarah Hanson

Co-Chair Life Sciences & Healthcare Sector

CMS Cameron McKenna Nabarro Olswang LLP
Cannon Place
78 Cannon Street
United Kingdom
Languages English

Sarah Hanson is a Partner in the Technology team and is the UK representative for the management committee of the CMS Commercial Group. She works across a number of sectors but has a particular focus on life sciences & healthcare and consumer products.  She is Co-chair of the UK Life Sciences & Healthcare Sector Group.

She has specialised in high value, cross-border commercial, intellectual property and outsourcing transactions for more than 20 years having advised on a broad range of commercial agreements relating to in and out licensing, sales and distributor arrangements, research and development, manufacturing and supply, strategic alliances and joint ventures.  During her time with the firm she has been on secondment with Warner Lambert (now part of Pfizer). 

more less

Sarah was also the exclusive winner of the Healthcare and Lifescience category for the UK of the International Law Office (ILO) Client Choice Awards.

Client Choice Awards

Sarah is ranked in Band 2 as a leading practitioner in the Lifesciences – Transactional category in Chambers where sources say she is “rock solid and praise her for her commercial approach” (2016 edition).

"Sarah is ranked as a leading practitioner for licensing work on the basis that she “has forged a strong name in transactions for patent-rich practitioners”."

IAM 1000 top patent practitioners.

Sarah has been recommended in a number of directories including PLC which Lawyer? Lifesciences the PLC Lifesciences Handbook and Legal 500 that described her as “delightful, very responsive and helpful”.

Sarah is ranked as a leading individual in Who’s Who Legal: Lifesciences – Transactional (2016 edition).

Relevant experience

  • Almirall SA on the transfer of its respiratory franchise to AstraZeneca for an initial consideration of USD 875m on completion and up to USD 1.22bn in development, launch and sales related milestone payments.
  • PGT Healthcare LLP in relation to a collaboration with Swisse Wellness Group Party Limited in relation to vitamin, mineral and food supplement products across certain territories.
  • Sinclair IS Pharma plc on an exclusive 100 year distribution arrangement with an affiliate of Valeant Pharmaceuticals International, Inc, for injectable aesthetic dermal filler products in Western Europe.
  • Takeda Pharmaceutical on its EUR 9.6bn (debt-free cash free) acquisition of Swiss drug company, Nycomed.
  • A retail company in relation to a comprehensive IT transformation project with a value of between GBP 1-2bn.  The new IT operating model involves the appointment of a ‘service integrator’ supplier who will manage and integrate all IT services.  The project also involves appointment of multiple IT “service tower” providers.  This includes the following IT services: (i) End User Computing services; (ii) Network services (telecoms networks across company’s entire estate); (iii) Front Office services (front office IT applications including cash and stock management, retail and stock sales, branch accounting); and (iv) Back Office services (back office IT applications including HR, accounting and finance systems).
  • Futura Medical, an AIM listed company, in relation to the licensing of its CSD500 product to major pharmaceutical and healthcare group, including Church & Dwight and Ansell.  We have advised on the commercial agreements with contract manufacturers and own brand labellers as well as the associated technical and quality agreements.
  • Camelot in respect of the establishment of the Euro Millions lottery and related matters.
  • On the establishment of the Francis Crick Institute, a consortium of Cancer Research UK, the MRC, UCL and the Wellcome Trust, as a world leading establishment for medical research and innovation at Kings Cross, London, together with ongoing operational advice.
  • Nestlé Health Science on its licence agreement with Lipid Therapeutics for exclusive rights to develop and commercialise a new therapeutic for treating mild to moderate ulcerative colitis.
  • hVIVO plc, an AIM listed company, on its interests in PrEP Biopharm and also on PrEP Biopharm’s licensing arrangements with Janssen Pharmaceuticals with respect to technologies to be developed and commercialised for the treatment of a variety of respiratory viruses.
more less


  • 2004 – Intellectual Property Diploma, Bristol University, Bristol
  • 1994 – Distinction, The College of Law, LPC, Chester
  • 1993 – BA (Hons) Cantab Law 2:1, St John’s College, Cambridge
more less


  • ABHI
  • ABPI
  • Biotech Industry Association
  • Society for Computers & Law
  • TechUK
more less


  • European Biopharmaceutical Review – eHealth opportunities for the biopharmaceutical industry
more less

Lectures list

  • EU Pharma Law Conference – May 2015
more less


Show only
11 January 2017
Food and bever­age
Pro­gress on the Life Sci­ences Sec­tor Deal 2
The Of­fice for Life Sci­ences has pub­lished its Feb­ru­ary edi­tion of the Life Sci­ences In­dus­tri­al Strategy & Sec­tor Deal News­let­ter (the “News­let­ter”). The News­let­ter provides an up­date on how the strategy has pro­gressed since phase 2of the Life Sci­ences Sec­tor.
Our ehealth cap­ab­il­it­ies
Fur­ther guid­ance for life sci­ence com­pan­ies if there is no Brexit...
Up­dated guid­ance has been is­sued by the UK Medi­cines and Health­care products Reg­u­lat­ory Agency (MHRA) on how the UK would reg­u­late medi­cines, med­ic­al devices and clin­ic­al tri­als in the event that the UK leaves the EU on 29 March 2019 with no with­draw­al ar­range­ments.
CMS Glob­al Lifes­ci­ences For­um Re­port 2015
Launch of Life Sci­ences Sec­tor Deal 2
The In­dus­tri­al Strategy – Life Sci­ences Sec­tor Deal 2 re­port is broken down by themes with each identi­fy­ing what pro­gress has been made by each of the sec­tor and Gov­ern­ment. A sum­mary of these themes and the gen­er­al find­ings are set out be­low:   1.
CMS Glob­al Lifes­ci­ences For­um 2015
Shap­ing the fu­ture through in­nov­a­tion and col­lab­or­a­tion
NICE pub­lishes evid­ence stand­ards for di­git­al health tech­no­lo­gies
As di­git­al health in­nov­a­tions de­vel­op at an in­creas­ing rate, it is im­port­ant that they are clin­ic­ally ef­fect­ive and of­fer eco­nom­ic value. NICE has pub­lished evid­ence stand­ards for di­git­al health tech­no­lo­gies.
The An­ti­dote - Winter 2015
Di­git­al Health - The new reg­u­la­tion of med­ic­al soft­ware and apps
The new Med­ic­al Devices Reg­u­la­tion 2017/745 (“MDR”), which comes in­to force in May 2020, rep­res­ents a huge over­haul of the reg­u­lat­ory frame­work gov­ern­ing med­ic­al devices in the EU.   The com­pli­ance bur­den for man­u­fac­tur­ers and oth­er en­tit­ies in the sup­ply chain.
CMS Ex­pert Guide on War­ranties in Sup­ply Con­tracts
Gov­ern­ment Is­sues Brexit Tech­nic­al No­tice for Life Sci­ences
On 23 Au­gust 2018, the UK Gov­ern­ment (the "Gov­ern­ment") is­sued the first wave of its tech­nic­al pa­pers de­signed to provide guid­ance to com­pan­ies to help pre­pare for a "No Deal" Brexit. In this scen­ario, there will be no "trans­ition peri­od" but rather the UK.